Eisai
エーザイ
Business focus
MedTech, BioTech & Pharma
Description
Eisai Co., Ltd. was founded on 6 December 1941 and is headquartered in Tokyo; it is a global leader in neurology and dementia research. In partnership with Biogen, Eisai developed lecanemab (Leqembi), which received US traditional approval in 2023 as the first therapy confirmed to slow cognitive decline in early Alzheimer's disease. Group revenue was about ¥741.8 billion in FY2023, with Leqembi sales growing rapidly (reported +153% year-over-year in H1 FY2026).